Combined Detection of CA19–9 and MUC1 Using a Colorimetric Immunosensor Based on Magnetic Gold Nanorods for Ultrasensitive Risk Assessment of Pancreatic Cancer

We herein report a facile approach for developing an enzyme-free colorimetric immunosensor based on a magnetic iron oxide (IO)-coated gold nanorod (MGNR) nanocomposite with high electron transfer ability to accelerate the color bleaching reaction of methyl orange (MO) in the presence of NaBH4 for ultrasensitive detection of cancer antigens. In the case of MO, the reaction rate of MGNRs showed approximately 45.6-fold and 1520.8-fold higher than that of Cys-GNRs and NaBH4, respectively. The proposed colorimetric immunosensor was demonstrated to enable simple, cost-effective, sensitive, and specific carbohydrate antigen 19–9 (CA19–9) and mucin 1 (MUC1) detection for risk evaluation of pancreatic cancer (PC) with a small volume of serum sample without the use of any enhancing solutions or enzymes. By increasing the concentration of CA19–9 and MUC1, more MGNRs remained in the plate well to enhance the color bleaching of MO. As a proof-of-concept, the limit of detection (LOD) of 3.5 × 10–5 U/mL for CA19–9 and 5.2 × 10–6 U/mL for MUC1 was obtained with a wide linear quantification range from 8.6 × 10–5 U/mL to 1.4 × 10–2 U/mL for CA19–9 and 1.3 × 10–5 U/mL to 2.1 × 10–3 U/mL for MUC1, suggesting potential clinical applications for the early risk evaluation of PC

Table_1_The mortality risk in patients with early onset colorectal cancer: the role of comorbidities.docx

The global incidence of early-onset colorectal cancer (EO-CRC) is increasing. Although the mortality rate is relatively stable, some comorbidities have been associated with a higher mortality rate. This study estimated the mortality risk in patients with EO-CRC with various comorbidities using real-world data to identify the high-risk group using Cox proportional regression for overall and cancer-specific mortality. The incidence rate of EO-CRC significantly increased from 6.04 per 100,000 population in 2007 to 12.97 per 100,000 population in 2017. The five-year overall mortality rate was 101.50 per 1000 person year and the cancer-specific mortality rate was 94.12 per 1000 person year. Patients with cerebrovascular disease (CVD) had a higher mortality risk (hazard ratio (HR): 1.68; 95% confidence interval (CI): 1.25-2.28; p=0.0007). After subgroup analyses based on age, sex, clinical stage, and treatment type, patients with CVD had a higher overall mortality risk compared to non-CVD patients, except for patients undergoing surgery and chemotherapy. Patients with chronic kidney disease had a higher mortality risk in the early clinical stages (HR: 2.31; 95% CI: 1.08-4.96; p=0.0138). Patients who underwent radiotherapy had a higher overall mortality risk (HR: 1.38; 95% CI: 1.04-1.85; p=0.0285) than those without liver disease. Identifying specific comorbidity mortality risks in patients with EO-CRC allows for risk stratification when screening target groups and may lower disease mortality.</p

Table_2_The mortality risk in patients with early onset colorectal cancer: the role of comorbidities.docx

The global incidence of early-onset colorectal cancer (EO-CRC) is increasing. Although the mortality rate is relatively stable, some comorbidities have been associated with a higher mortality rate. This study estimated the mortality risk in patients with EO-CRC with various comorbidities using real-world data to identify the high-risk group using Cox proportional regression for overall and cancer-specific mortality. The incidence rate of EO-CRC significantly increased from 6.04 per 100,000 population in 2007 to 12.97 per 100,000 population in 2017. The five-year overall mortality rate was 101.50 per 1000 person year and the cancer-specific mortality rate was 94.12 per 1000 person year. Patients with cerebrovascular disease (CVD) had a higher mortality risk (hazard ratio (HR): 1.68; 95% confidence interval (CI): 1.25-2.28; p=0.0007). After subgroup analyses based on age, sex, clinical stage, and treatment type, patients with CVD had a higher overall mortality risk compared to non-CVD patients, except for patients undergoing surgery and chemotherapy. Patients with chronic kidney disease had a higher mortality risk in the early clinical stages (HR: 2.31; 95% CI: 1.08-4.96; p=0.0138). Patients who underwent radiotherapy had a higher overall mortality risk (HR: 1.38; 95% CI: 1.04-1.85; p=0.0285) than those without liver disease. Identifying specific comorbidity mortality risks in patients with EO-CRC allows for risk stratification when screening target groups and may lower disease mortality.</p

Sociodemographic characteristics and comorbidities in the tSCI group and other health conditions group.

<p>Sociodemographic characteristics and comorbidities in the tSCI group and other health conditions group.</p

Cox model for the risk of anxiety or depression by the different levels of tSCI compared with other health conditions and tSCI only.

<p>Cox model for the risk of anxiety or depression by the different levels of tSCI compared with other health conditions and tSCI only.</p

Kaplan-Meier plot for anxiety or depression occurrence for tSCI and the other health conditions groups.

(a) anxiety/depression-free survival curves for patients with the spinal cord injury (tSCI patients, n = 3,556) and the other health conditions groups (n = 3,556) during the 3-year follow up period (p = .0009). (b) The significant level was set at p < .05. (c) It showed that the SCI patients had a significantly higher risk of new-onset anxiety or depression than the other health conditions group.</p

sj-docx-1-onc-10.1177_11795549221111713 – Supplemental material for Impact of Tumor Location on Survival in Patients With Colorectal Cancer: A Retrospective Cohort Study Based on Taiwan’s Cancer Registry Database

Supplemental material, sj-docx-1-onc-10.1177_11795549221111713 for Impact of Tumor Location on Survival in Patients With Colorectal Cancer: A Retrospective Cohort Study Based on Taiwan’s Cancer Registry Database by Shou-Chun Yu, Kuang-Ming Liao, Chia-Lin Chou, Yu-Feng Tian, Jhi-Joung Wang, Chung-Han Ho and Yow-Ling Shiue in Clinical Medicine Insights: Oncology</p

Sociodemographic characteristics and comorbidities in the tSCI group and other health conditions group.

<p>Sociodemographic characteristics and comorbidities in the tSCI group and other health conditions group.</p

Incidence rate for anxiety or depression between the tSCI group and other health conditions group.

<p>Incidence rate for anxiety or depression between the tSCI group and other health conditions group.</p

Supplementary Methods, Tables, and Figure Legends from Transmembrane and Coiled-Coil Domain 1 Impairs the AKT Signaling Pathway in Urinary Bladder Urothelial Carcinoma: A Characterization of a Tumor Suppressor

The file includes Supplementary Methods, Tables, and Figure Legends. Table S1. TMCO1 is identified as a differentially expressed transcript with molecular function of growth factor activity (GO:0008083) and low expression levels shows positive correlations to cancer invasiveness and metastasis in the transcriptome of urothelial carcinoma of urinary bladder (GSE31684) Table S2. Correlations between the TMCO1 protein level and important clinicopathological parameters in urothelial carcinomas Table S3. TMCO1 promoter methylation detected by pyrosequencing in urothelial cancer cells and tissues</p